C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes.

What Was Tested

The paper reports a study of C-Peptide, published as a randomized controlled trial.

Myocardial contrast echocardiography was used for assessment of myocardial blood volume (SI(max)) and myocardial blood flow index (MBFI) calculated from the relation between trigger interval and signal intensity.

Eight age-matched healthy volunteers served as control subjects.

Who Took Part

PubMed indexes the participants as adults, men only.

Myocardial dysfunction, perfusion abnormalities, and the extent to which these abnormalities may be reversed by C-peptide administration was assessed in type 1 diabetic patients.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

Because people in this C-Peptide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received C-Peptide.

In the crossover set-up each of the participants took both C-Peptide and the comparison in turn, acting as their own control.

Myocardial function was measured as peak myocardial velocity during systole (Vs) and early diastole (Vd) by pulsed tissue Doppler imaging.

What Was Measured

Myocardial contrast echocardiography was used for assessment of myocardial blood volume (SI(max)) and myocardial blood flow index (MBFI) calculated from the relation between trigger interval and signal intensity.

PubMed files the paper under topics including Blood Glucose, Blood Pressure, C-Peptide, Coronary Circulation, Diabetes Mellitus, Type 1, Echocardiography and Heart Rate.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of C-Peptide.

The publication is from 2002 (Diabetes), a journal based in United States.

More context: the C-Peptide compound page, all human trials.